![Igor Matushansky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Igor Matushansky
Chief Tech/Sci/R&D Officer at
IMMUNEERING CORPORATION
Net worth: - $ as of 31/05/2026
Profile
Igor Matushansky currently works at Crescendo Biologics Ltd., as Non-Executive Director from 2018, The Trustees of Columbia University in The City of New York, as Assistant Professor, and Immuneering Corp., as Chief Medical Officer from 2025.
Dr. Matushansky also formerly worked at Ipsen SA, as Senior VP & Head-Oncology Development from 2022 to 2023, Daiichi Sankyo, Inc., as Global Head-Oncology Early Development from 2015 to 2017, HOOKIPA Pharma, Inc., as Chief Medical Officer & Global Head-Research from 2017 to 2022, Sail Biomedicines Inc, as Chief Medical Officer from 2023 to 2025, and Columbia University Irving Medical Center, as Professor from 2007 to 2012.
Dr. Matushansky received his undergraduate degree from The Trustees of Columbia University in The City of New York and doctorate degree from Albert Einstein College of Medicine, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 03/02/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Igor Matushansky active positions
| Companies | Position | Start |
|---|---|---|
| IMMUNEERING CORPORATION | Chief Tech/Sci/R&D Officer | 20/03/2025 |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Director/Board Member | 02/07/2018 |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Former positions of Igor Matushansky
| Companies | Position | End |
|---|---|---|
Sail Biomedicines
 Sail Biomedicines Pharmaceuticals: MajorHealth Technology Engages in design and deployment of programmable medicines | Chief Tech/Sci/R&D Officer | 01/01/2025 |
| IPSEN | Corporate Officer/Principal | 01/06/2023 |
| HOOA PHARPAR | Chief Tech/Sci/R&D Officer | 30/06/2022 |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Corporate Officer/Principal | 01/04/2017 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Corporate Officer/Principal | 01/11/2015 |
Training of Igor Matushansky
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
88
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Health Technology |
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia University Medical Center
 Columbia University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Commercial Services |
Immuneering Corp.
 Immuneering Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, focuses on the oncology and neuroscience product candidates | Health Technology |
HOOKIPA Pharma, Inc.
 HOOKIPA Pharma, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company which develops pharmaceutical products for immunotherapeutics targeting infectious diseases and cancers | Health Technology |
Sail Biomedicines
Sail Biomedicines Pharmaceuticals: MajorHealth Technology Engages in design and deployment of programmable medicines | Health Technology |
- Stock Market
- Insiders
- Igor Matushansky
